Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Revenue (2024 - 2025)

Indivior Pharmaceuticals has reported Revenue over the past 2 years, most recently at $358.0 million for Q4 2025.

  • Quarterly results put Revenue at $358.0 million for Q4 2025, up 19.73% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 4.29% YoY), and the annual figure for FY2025 was $1.2 billion, up 4.29%.
  • Revenue for Q4 2025 was $358.0 million at Indivior Pharmaceuticals, up from $314.0 million in the prior quarter.
  • Over the last five years, Revenue for INDV hit a ceiling of $358.0 million in Q4 2025 and a floor of $266.0 million in Q1 2025.